Project Grant K99CA303782
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$113K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $139,917 to the University of Chicago to investigate how the dietary nutrient zeaxanthin can enhance anti-tumor immunity by reprogramming CD8+ T cell function. The research aims to demonstrate zeaxanthin's anti-tumor effects in preclinical models, elucidate the molecular mechanisms underlying zeaxanthin's impact on CD8+ T cell function, and explore strategies to improve cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $130,501 to The Salk Institute for Biological Studies to conduct research on the role of muscle CDKN1A in cancer cachexia. The key objectives are to: 1) elucidate the function of muscle CDKN1A in muscle dysfunction during cancer cachexia, 2) define the temporal regulation of CDKN1A by BCL6 in response to nutrient availability, and 3) assess immune modulation of muscle CDKN1A as a...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $563,233 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Medical University of South Carolina. The 5-year grant, which commenced on April 1, 2025, supports research to investigate how the sphingosine kinase 2 (SPHK2)/sphingosine-1-phosphate (S1P) axis regulates the immunosuppressive function of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. The key objectives...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a Project Grant in the amount of $145,336 to the Sloan-Kettering Institute for Cancer Research located in New York. The grant, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors," will fund research focused on reprogramming hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Research Manpower (CFDA 93.398) program, supports research to decipher the immune evasion mechanisms of cancers harboring mutations in the IDH1 gene. The $196,029 award, effective April 1, 2025 through March 31, 2028, will fund the University of Massachusetts Medical School's investigation into two key processes that contribute to the immunosuppressive tumor microenvironment in IDH1-mutant cancers: 1) the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $730,398 to the Sloan-Kettering Institute for Cancer Research to investigate the relationship between leptomeningeal cancer cell growth and inflammatory signaling in the leptomeningeal space. The research aims to mechanistically dissect the CXCL1-CXCR2 signaling axis within the leptomeningeal space, identify cancer cell signals that provoke leptomeningeal CXCL1 generation, and...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...